Fremanezumab

• 收藏
• 分享

专利权人:

Teva Pharmaceuticals International GmbH

发明人:

申请号：

NO2019043

公开号：

NO2019043I1

申请日:

2019.12.09

申请国别(地区):

NO

年份:

2019

代理人:

摘要：

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/